Changes in Beneficial Ownership · 4
Monte Rosa Therapeutics, Inc.
GLUENASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-06-11
- Issuer
- Monte Rosa Therapeutics, Inc.
- Issuer CIK
- 0001826457
- Trading symbol
- GLUE
Reporting owner 1
- Name
- Behbahani Ali
- Reporting owner CIK
- 0001613867
- Relationship
- Director
- Address
- 2855 SAND HILL ROAD, MENLO PARK, CA, 94025
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 17.10 | 2026-06-11 | A · Form 4 | 25,800 | A | 0 | [F1] | 2036-06-11 | Common Stock | 25,800 | 25,800 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.↩ 1
Signature 1
- Signed
- /s/ Zachary Bambach, attorney-in-fact
- Date
- 2026-06-12
Company context
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology, and neurology. For more information, visit www.monterosatx.com.